Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 392, Issue 3, pp 287–297 | Cite as

CCR2 and CCR5 promote diclofenac-induced hepatotoxicity in mice

  • Zhanke He
  • Guoquan Wei
  • Na Li
  • Mengwei Niu
  • Shenhai Gong
  • Guangyan Wu
  • Teng Wang
  • Yong JiangEmail author
  • Peng ChenEmail author
Original Article
  • 77 Downloads

Abstract

Liver injury, one of the major side effects of diclofenac (DIC), plagues thousands of patients who treated with it. Although involvements of metabolic factors, oxidative stress, and mitochondrial injury have been characterized, the exact immunomolecular mechanism of the hepatotoxicity of DIC still remains ambiguous. In this study, we investigated the role of chemokine receptors CCR2 and CCR5 in this progression. Ccr2, Ccr5, and Tnfr1/2-deficient mice, as well as wild type littermates, were administrated DIC or vehicle for 24 h, receptively. Hepatic expression of CCR2, CCR5, and their ligands were upregulated after DIC treatment. DIC-induced liver injury was augmented in Ccr2+/+ mice than Ccr2−/− mice, a similar phenotype was observed in Ccr5-deficient mice. In addition, antagonists of CCR2 or CCR5 protected liver damage caused by diclofenac. Besides, the number of neutrophils present in the liver was gradually increased from 0 to 12 h after drug administration. However, the recruitment of neutrophils was dramatically lessened after blocking CCR2 or CCR5 signaling. Furthermore, TNF-α level in the liver was decreased in Ccr2−/− mice compared with Ccr2+/+ mice. Intriguingly, in line with this, TNF receptor 1 and 2 double knockout mice showed markedly attenuated hepatotoxicity of DIC. These suggested that CCR2 and CCR5 mediated hepatotoxicity induced by diclofenac, TNF-α was responsible, at least in part, for it, and the pharmacological inhibition of CCR2 or CCR5 might serve as a novel therapeutic approach for DIC-induced hepatotoxicity.

Keywords

Diclofenac Acute liver injury CCR2 CCR5 Neutrophils TNF-α 

Notes

Author contribution statement

ZH, GW, NL, MN, and SG conducted experiments. YJ and PC conceived and designed the research. GW and TW analyzed the data. ZH, GW, and PC wrote the manuscript. All authors read and approved the manuscript.

Funding information

This study was supported in part by the Natural Science Funds for Distinguished Young Scholar of Guangdong province (2016A030306043), the award of Young Pearl Scholars of Guangdong province, and the funding from State Key Laboratory of Organ Failure Research (201804) to PC. The Grant of NSFC-Guangdong Joint Foundation of China (U1601225), National Natural Science Foundation of China (81372030), and Key Scientific and Technological Program of Guangzhou City (201607020016) to JY.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

All experiments were performed according to the National Institutes of Health guidelines and were approved by the Southern Medical University Experimental Animal Ethics Committee.

References

  1. Aithal GP (2004) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 192:307–322Google Scholar
  2. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JBS, Alexander G, Kenna JG, Caldwell J, Day CP (2004) Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39:1430–1440CrossRefGoogle Scholar
  3. Akingbasote JA, Foster AJ, Wilson I, Sarda S, Jones HB, Kenna JG (2016) Hepatic effects of repeated oral administration of diclofenac to hepatic cytochrome P450 reductase null (HRN) and wild-type mice. Arch Toxicol 90:853–862CrossRefGoogle Scholar
  4. Antoniades CG, Berry PA, Wendon JA, Vergani D (2008) The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol 49:845–861CrossRefGoogle Scholar
  5. Bachmann MF, Kopf M, Marsland BJ (2006) Chemokines: more than just road signs. Nat Rev Immunol 6:159–164CrossRefGoogle Scholar
  6. Banks AT, Zimmerman HJ, Ishak KG, Harter JG (1995) Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 22:820–827CrossRefGoogle Scholar
  7. Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214:149–160CrossRefGoogle Scholar
  8. Cantoni L, Valaperta R, Ponsoda X, Castell JV, Barelli D, Rizzardini M, Mangolini A, Hauri L, Villa P (2003) Induction of hepatic heme oxygenase-1 by diclofenac in rodents: role of oxidative stress and cytochrome P-450 activity. J Hepatol 38:776–783CrossRefGoogle Scholar
  9. Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610–621CrossRefGoogle Scholar
  10. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP (2007) Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132:272–281CrossRefGoogle Scholar
  11. Deng X, Stachlewitz RF, Liguori MJ (2006) Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 319:1191–1199CrossRefGoogle Scholar
  12. Eun-Hee L, Jung-Hwa O, Saravanakumar S et al (2016) Immunogenomics reveal molecular circuits of diclofenac induced liver injury in mice. Oncotarget 7:14983–15017Google Scholar
  13. Ghosh R, Goswami SK, Feitoza LF, Hammock B, Gomes AV (2016) Diclofenac induces proteasome and mitochondrial dysfunction in murine cardiomyocytes and hearts. Int J Cardiol 223:923–935CrossRefGoogle Scholar
  14. Goulding C, McManus R, Murphy A, MacDonald G, Barrett S, Crowe J, Hegarty J, McKiernan S, Kelleher D (2005) The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 54:1157–1161CrossRefGoogle Scholar
  15. Grommes J, Drechsler M, Soehnlein O (2014) CCR5 and FPR1 mediate neutrophil recruitment in endotoxin-induced lung injury. J Innate Immun 6:111–116CrossRefGoogle Scholar
  16. Guicciardi ME, Malhi H, Mott JL, Gores GJ (2013) Apoptosis and necrosis in the liver. Compr Physiol 3:977–1010Google Scholar
  17. Kolaczkowska E, Kubes P (2013) Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13:159–175CrossRefGoogle Scholar
  18. Kretz-Rommel A, Boelsterli UA (1995) Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic hepatocytes exposed to diclofenac. Hepatology 22:213–222CrossRefGoogle Scholar
  19. Lazarska KE, Dekker SJ, Vermeulen N, Commandeur J (2018) Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism. Toxicol Lett 284:70–78CrossRefGoogle Scholar
  20. Lee YK, Choi DY, Jung YY, Yun YW, Lee BJ, Han SB, Hong JT (2013) Decreased pain responses of C-C chemokine receptor 5 knockout mice to chemical or inflammatory stimuli. Neuropharmacology 67:57–65CrossRefGoogle Scholar
  21. Mack M, Cihak J, Simonis C, Luckow B, Proudfoot AEI, Plachy J, Bruhl H, Frink M, Anders HJ, Vielhauer V, Pfirstinger J, Stangassinger M, Schlondorff D (2001) Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol 166:4697–4704CrossRefGoogle Scholar
  22. Masubuchi Y, Nakayama S, Horie T (2002) Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 35:544–551CrossRefGoogle Scholar
  23. Mathijs K, Kienhuis AS, Brauers KJ, Jennen DG, Lahoz A, Kleinjans JC, van Delft JH (2009) Assessing the metabolic competence of sandwich-cultured mouse primary hepatocytes. Drug Metab Dispos 37:1305–1311CrossRefGoogle Scholar
  24. Oda S, Shirai Y, Akai S, Nakajima A, Tsuneyama K, Yokoi T (2017) Toxicological role of an acyl glucuronide metabolite in diclofenac-induced acute liver injury in mice. J Appl Toxicol 37:545–553CrossRefGoogle Scholar
  25. Olson TS, Ley K (2002) Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 283:R7–R28CrossRefGoogle Scholar
  26. Purcell P, Henry D, Melville G (1991) Diclofenac hepatitis. Gut 32:1381–1385CrossRefGoogle Scholar
  27. Raghu H, Lepus CM, Wang Q, Wong HH, Lingampalli N, Oliviero F, Punzi L, Giori NJ, Goodman SB, Chu CR, Sokolove JB, Robinson WH (2017) CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis. Ann Rheum Dis 76:914–922CrossRefGoogle Scholar
  28. Reichel CA, Khandoga A, Anders HJ, Schlondorff D, Luckow B, Krombach F (2006) Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue. J Leukoc Biol 79:114–122CrossRefGoogle Scholar
  29. Saiman Y, Friedman SL (2012) The role of chemokines in acute liver injury. Front Physiol 3:213CrossRefGoogle Scholar
  30. Schwabe RF, Brenner DA (2006) Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 290:G583–G589CrossRefGoogle Scholar
  31. Seki E, De Minicis S, Gwak GY et al (2009a) CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 119:1858–1870Google Scholar
  32. Seki E, de Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N, Schwabe RF, Brenner DA (2009b) CCR2 promotes hepatic fibrosis in mice. Hepatology 50:185–197CrossRefGoogle Scholar
  33. Selvaraj S, Oh JH, Spanel R et al (2017) The pathogenesis of diclofenac induced immunoallergic hepatitis in a canine model of liver injury. Oncotarget 8:107763CrossRefGoogle Scholar
  34. Smith MW, Dean M, Carrington M et al (1997) Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia growth and development study (HGDS), multicenter AIDS cohort study (MACS), multicenter hemophilia cohort study (MHCS), San Francisco City cohort (SFCC), ALIVE study. Science 277:959–965CrossRefGoogle Scholar
  35. Yang SJ, Iglayreger HB, Kadouh HC, Bodary PF (2009) Inhibition of the chemokine (C–C motif) ligand 2/chemokine (C–C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy. Diabetologia 52:972–981CrossRefGoogle Scholar
  36. Yang D, Tong L, Wang D, Wang Y, Wang X, Bai C (2010) Roles of CC chemokine receptors (CCRs) on lipopolysaccharide-induced acute lung injury. Respir Physiol Neurobiol 170:253–259CrossRefGoogle Scholar
  37. Yano A, Higuchi S, Tsuneyama K, Fukami T, Nakajima M, Yokoi T (2012) Involvement of immune-related factors in diclofenac-induced acute liver injury in mice. Toxicology 293:107–114CrossRefGoogle Scholar
  38. Zamara E, Galastri S, Aleffi S, Petrai I, Aragno M, Mastrocola R, Novo E, Bertolani C, Milani S, Vizzutti F, Vercelli A, Pinzani M, Laffi G, LaVilla G, Parola M, Marra F (2007) Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J Hepatol 46:230–238CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Zhanke He
    • 1
  • Guoquan Wei
    • 1
  • Na Li
    • 1
  • Mengwei Niu
    • 1
  • Shenhai Gong
    • 1
  • Guangyan Wu
    • 1
  • Teng Wang
    • 1
  • Yong Jiang
    • 1
    Email author
  • Peng Chen
    • 1
    Email author
  1. 1.Department of Pathophysiology, Guangdong Provincial Key Laboratory of ProteomicsSouthern Medical UniversityGuangzhouChina

Personalised recommendations